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The incidence of breast cancer has been increasing since the 1960s
at the global level. The 5-year survival rate is generally low in
stage III breast cancer patients, and extremely low in the stage IV
patients, regardless of different treatment modalities including
hormone therapy, chemotherapy and radiotherapy. Therefore,
development of new treatment modalities is needed, and one of
them will be specific immunotherapy (Nestle et al, 1998;
Rosenberg et al, 1998; Marchant et al, 1999). However, little infor-
mation is available regarding tumour-rejection antigens on breast
cancers. Many tumour-rejection antigens have been identified
from melanomas (van der Bruggen et al, 1991, 1994; Traversari et
al, 1992; Kawakami et al, 1994, 1995; Robbins et al, 1996, 1997),
but these antigens were rarely expressed in breast cancers
(Vincenzo et al, 1995). SART1259 antigen that was identified from
an oesophageal cancer was also rarely expressed in breast cancers
(Kawamoto et al, 1999). MUC1 antigen and HER2/neu oncogene
products might encode a tumour epitope on HLA-A2+ breast
cancers (David et al, 1995; Reddish et al, 1998), but the peptide
specificity and HLA-restriction have not been clearly demon-
strated. 
We recently reported that the SART3 tumour-rejection anti-
gen possesses tumour epitopes capable of inducing HLA-A24-
restricted CTLs in head and neck cancer patients (Yang et al,
1999). The 140 kD of the SART3 antigen was expressed in the
nucleus of all of the malignant cell lines and in the majority of
cancer tissues tested, but not in the nucleus of any of the normal
tissues except that of the testis. It was also expressed in the cytosol
of the majority of proliferating cells, including normal cells and
malignant cells. 
In this study, we investigated expression of the SART3 antigen
in breast cancer tissues to explore for an appropriate molecule
useful for specific immunotherapy of breast cancer, and found
evidence suggesting that the SART3 could be an appropriate target
molecule. 
MATERIALS AND METHODS 
Samples 
The eight breast cancer cell lines used in this study were MCF7, R27,
OCUB-M, OCUB-F, YMB-1-E, CRL1500, MDA-MB-231 and T-
47D. These cell lines were incubated with RPMI 1640 medium, EME
medium, or Dulbecco’s Modified Eagle’s Medium supplemented with
10% FCS, included in these cell lines reported (Kawamoto et al, 1999).
The HLA-A2402+ tumours are OCUB-M and OCUB-F. 
Breast cancer tissue samples (n = 40) and non-tumourous breast
tissue samples (n = 3) were obtained at the time of surgery in the
Kurume University Hospital. All of the cancers were histologically
determined to be adenocarcinoma. In samples, stage I and stage II
group numbered 23 cases and stage III and stage IV numbered 17
cases. A section of each sample was minced with scissors and kept
at –80˚C until use. The KE -4 oesophageal squamous carcinoma
cell line (HLA-A2402/A2601) from which the SART3 was cloned
(Yang et al, 1999) was used as a positive control. VA13 fibroblast
cells (no expression of HLA-class I alleles), and CIR-A402 cells
were used as target cells as negative controls, as reported previ-
ously (Yang et al, 1999; Murayama et al. 2000). 
Western blot analysis 
Expression of the SART3 antigen in samples was investigated by
Western blot analysis using the polyclonal anti-SART3 antibody
as reported previously (Yang et al, 1999). 
Expression of oestrogen and progesterone receptors 
Expression of the oestrogen or progesterone receptors in frozen
sections was measured using the standard enzyme immunoassay
commercially available from SRL (Tokyo). For the assays Abbot
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according to the manufacturer’s instructions. The international
UICC-TNM system was used for staging the 31 breast cancer
patients. 
Peptides and CTL induction 
The SART3109–118 (VYDYNCHVDL) and SART3315–323 (AYID-
FEMKI) peptides were used for CTL induction as described previ-
ously (Yang et al, 1999). PBMCs from breast cancer patients
(n = 4) were incubated with 10 mM of a peptide in one well of a
24-well plate containing 2 ml of culture medium with 100 units
ml–1 of IL-2 (Shiongi Pharm Co, Osaka). At days 7, 14 and 21 of
culture, the cells were harvested, washed and re-incubated with the
irradiated (45 Gy) autologous PBMCs acting as antigen-
presenting cells, which had been pre-incubated with the same
peptide at the same dose for 3 h. These peptide-stimulated PBMCs
(2–3 ´ 103 cells well–1) were harvested at day 28 of culture, and
further cultured in a 96-well U-bottom microculture plate in the
presence of feeder cells (irradiated HLA-A24+ PBMCs) that had
been pre-pulsed with a corresponding peptide in order to obtain
large numbers of effector cells. Seven to 10 days later, the
expanded cells were transferred to wells of a 24-well plate and
were incubated in the absence of either a peptide or feeder cells for
an additional 21–28 days. 
The surface phenotypes and CTL activity of these cells was
tested by an IFN-g production assay (limit of sensitivity = 10 pg
ml–1), and 51Cr-labelled assays at different E:T ratios at the tripli-
cate assays. For preparation of CTL sublines, the peptide-stimu-
lated PBMCs were incubated at 1 or 10 or 100 cells per well in the
presence of irradiated HLA-A24 PBMCs (2–3 ´ 105 cells well–1)
that were pre-loaded with a relevant peptide, followed by testing
of their surface phenotype and CTL activity to produce IFN-g in
response to CIR-A2402 pre-loaded with a peptide. 
The surface phenotype of effector cells was investigated by an
immunofluorescence assay with FITC-conjugated anti-CD3, -CD4
or -CD8 mAb (Yang et al, 1999). For inhibition of CTL activity,
20 mg ml–1 of anti-class I (W6/32, IgG2a) or anti-CD8 (IgG2a),
anti-class II (H-DR-1, IgG2a) and anti-CD4 (IgG1) mAb were
used as reported previously. Anti-CD13 (MCS-2, IgG1) and anti-
CD14 (H14, IgG2a) mAb were used as isotype-matched control
mAb. 
RESULTS 
Expression of SART3 antigen 
The 140 kD of the SART3 antigen was expressed in both the
cytosol and nuclear fractions of all eight breast cancer cell lines
tested. This band was also detectable in the cytosol fraction of 28
of 40 (70%) breast cancer tissue samples, and in the nuclear frac-
tion of 30 of 40 (75%) breast cancer tissue samples. The bands
other than the 140 kD, which were observed in cancer samples,
were evaluated as non-specific since the polyclonal antibody was
used for the detection. 
The expression of SART3 antigen in the group of stage I and II
was 18 of 23 samples (78.3%) in the cytosol, and 19 of 23
samples (82.6%) in the nucleus, while that in the group of the
stage III and IV was 10 of 17 samples (58.8%) in the cytosol, and
11 of 17 samples (64.7%) in the nucleus. However, it was not
detectable in either the cytosol or nuclear fraction of any of the
normal breast tissue samples tested. Examples of results are
shown in Figure 1, and a summary of these results is presented in
Table 1. 
Expression of oestrogen or progesterone receptors 
The expression of oestrogen receptor (ER) or progesterone
receptor (PR) in these tumours was investigated in view of poten-
tial combined immunotherapy and hormone therapy. Twenty-three
and 17 of the 31 breast cancer tumours expressed ER and PR,
respectively (Table 1). Among the 31 tumours, 16 tumours were
SART3+ and ER+, two tumours were SART3+ and ER–, seven
tumours were SART3– and ER+. The remaining six tumours were
SART3– and ER–. Similarly, 11 tumours were SART3+ and PR+,
seven tumours were SART3+ and PR–, six tumours were SART3–
and PR+, and seven tumours were SART3– and PR–.
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Table 1 Expression of SART3 antigen in breast cancer 
Samples Numbers SART3 antigen expression 
Oestrogen Progesterone
Cytosol Nucleus receptor receptor 
Breast cancer cell lines 8 8/8 8/8 ND ND 
Stage I, II 23 18/23 (78.3%) 19/23 (82.6%)  16/19 (84.2%) 13/19 (68.4%) 
Breast cancer tissues Stage III, IV 17 10/17(58.8%) 11/17 (64.7%) 8/12 (66.7%) 4/12 (33.3%) 
Total 40 28/40 (70.0%) 30/40 (75.0%) 23/31(74.2%)  17/31(54.8%) 
Non-tumourous breast tissues 3 0/3 0/3 ND ND 
ND = not determined; percentages of positive 
K
E
4
P
B
M
C
M
C
F
7
R
2
7
O
C
U
B
-
M
C
R
L
1
5
0
0
Y
M
B
-
1
-
E
O
C
U
B
-
F
T
-
4
7
D
M
D
A
-
M
B
-
2
3
1
B
C
1
B
C
2
N
o
r
m
a
l
 
t
i
s
s
u
e
140 kD
140 kD
Cytosol
Nucleus
Figure 1 Expression of the SART3 antigen in the breast cancer cell lines,
breast cancer tissue samples, and non- tumourous breast tissue samples
was investigated by Western blot analysis with polyclonal anti-SART3
antibody (Yang et al, 1999). Representative results of the investigation of
both cytosol and nuclear fractions are shown. PBMCs of a healthy donor
were used as a negative control and KE4 oesophageal cancer cells as a
positive control. Breast cancer cell lines included MCF7, R27, OCUB-M,
CRL1500, YMB-1-E, OCUB-F, T-47D, and MDA-MB-231. Breast cancer
tissues are shown as BC1 and BC2 in the figure, while non-tumour breast
tissue is shown as normal tissue. Induction of CTLs by the SART3 peptides 
The SART3109–118 and SART3315–323 peptides were tested for their
ability to induce CTLs from the PBMCs of HLA-A24+ patients
with breast cancer (n = 4, histologically-determined adenocarci-
noma). These PBMCs produced a significant level of IFN-g by
recognition of HLA-A24+ cancer cells (KE-4 and OCUB-M) when
stimulated in vitro with either SART3109–118 or SART3315–323 peptide
(Figure 2A). In contrast, they failed to react to HLA-A24– breast
cancer cells (R27). These effector cells consisted of 20–30%
CD3+CD4–CD8+ T cells and 70–80% CD3+CD4+CD8– T cells (data
not shown). The HLA-A24-restricted CTL activity in these
PBMCs was confirmed by a 6-h 51Cr release assay after further
expansion in patients 1 and 2. These peptide-stimulated PBMCs
showed significant levels of cytotoxicity against the HLA-A24+
tumour cells (KE-4 and OCUB-M), but not against HLA-A24–
tumour cells (VA13 and R27) (Figure 2B). 
The CTL activity was inhibited by anti-class I (W6/32) or 
anti-CD8 (Nu-TS/C), but not by anti-CD4 (Nu-TH/I), anti-class II
(DR), anti-CD13 (MCS-2) or anti-CD14 (H14) mAb, taken
as a negative control (Figure 2C). Further, CTL sublines were
established and tested for their reactivity to a peptide in order to
confirm the peptide specificity in the CTLs. 
One of six or three of 20 sublines from the PBMCs of patient 1,
when stimulated with the SART3109–118 peptide or SART3315–323
peptide, produced a significant amount of IFN-g by recognition of
C1R-A2402 cells pulsed with a corresponding peptide, respect-
ively (Figure 3A and B). Similarly, one of three or four of 20
sublines from PBMCs of patient 2, when stimulated with the
SART3109–118 peptide or SART3315–323 peptide, produced a significant
Induction of CTLs by SART3-derived peptides in breast cancer 917
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Figure 2 CTL activity of the peptide-induced PBMCs. PBMCs stimulated with SART3109–118 or SART3315–323 peptide were tested for their ability to recognize
breast cancer cells by IFN-g assay (A) and 6-h 51Cr release assay (B). (A) Values represent the mean of IFN-g produced from the peptide-stimulated PBMCs of
four breast cancer patients. Background IFN-g production by the PBMCs alone (50–100 pg ml–1) has been subtracted. (B) Values represent the mean of %
specific lysis of the triplicate determinants of the peptide-stimulated PBMCs of patients 1 and 2. Breast cancer cells used were OCUB-M (HLA-A2402+), and
R27 (HLA-A2402–). The KE4 tumour cell line was used as a positive control, while VA13 cell line was a negative control. (C) These PBMCs showing HLA-24-
restricted CTL activity were tested for their ability to produce IFN-g in response to HLA-24+ breast cancer cells (OCUB-M) at an E:T ratio of 2 in the presence of
20 mg ml–1 of anti-CD4 (Nu-TH/1), anti-CD8 (Nu-TS/C), anti-CD13 (MCS-2), anti-CD14 (H14), anti-class 1 (W6/32), or anti-class II (DR) mAb. Values represent
the mean of duplicate assays. The two-tailed Student’s t-test was employed for statistical analysis (*P ≤ 0.05) amount of IFN-g by recognition of C1R-A2402 cells pulsed with a
corresponding peptide, respectively (Figure 3C, D). 
DISCUSSION 
This study showed that the SART3 antigen encoding tumour
epitopes capable of inducing CTLs was expressed in both the
cytosol and nuclear fractions of all breast cell lines and the majority
of breast tumours tested. In contrast, this antigen was undetectable
in non-tumourous breast tissue samples. We recently obtained
evidence that this is a RNA-binding protein involved in splicing
regulation of RNA (Harada, unpublished results). These results
suggest that the SART3 antigen plays an important role in cellular
proliferation. This issue is now under investigation in our laboratory. 
The present study also showed that the SART3109–118 and
SART315–323 peptide induced HLA-A24-restricted CTLs recog-
nizing the SART3+ tumour cells including breast cancer cells in the
PBMCs of all HLA-A24+ breast cancer patients tested. These
CTLs failed to lyse either HLA-A24– tumour cells (Figure 2) or
HLA-A24+ normal T cells (PHA-blastic cells) (data not shown).
These results indicate the presence of CTL precursors reacting to
the SART3 epitope on breast cancer cells in the circulation of the
majority of breast cancer patients. 
In contrast to the SART3 antigen, the other tumour antigens
(MAGE-1, MAGE-4, SARTI259, MUC1) were expressed in only a
portion of breast cancers (Vincenzo et al, 1995; Reddish et al,
1998; Kawamoto et al, 1999). Further, no peptides were proven to
have the ability to induce HLA-class I restricted CTLs reacting to
breast cancer cells. Administration of HER2/neu peptide capable
of binding to HLA-A2 molecules failed to induce the CTL activity
against cancer cells (Zaks and Rosenberg, 1998). Therefore, the
SART3 antigen and its peptides could be one of the most
appropriate molecules for use in specific immunotherapy of breast
cancer patients. 
There are few treatment modalities available for patients with
breast cancer which is lacking ER or resistant to the existing
hormone therapy (Slamon et al, 1989; Teixeira et al, 1995;
Yamauchi et al, 1997). Among 31 tumours tested, 16 (52%)
expressed both SART3 and ER, two (7%) were SART3+ and ER–,
seven (23%) were SART3– and ER+, and six (19%) were SART3–
and ER–. These results suggest that a substantial proportion of
breast cancer patients would be appropriate candidates for
specific immunotherapy with the SART3 peptides, either admin-
istered independently or in combination with hormone therapy.
Similar results were obtained with PR. Further, SART3 expres-
sion in the group of stage I and II was higher than that in the
group of stage III and IV. A similar trend was observed in the
expression of ER and PR. These results suggest that both
immunotherapy and hormone therapy are more effective for
breast cancer patients with early stage rather than the patients
with advanced stage, although details involved in this phenom-
enon is not clear at the present time. 
The HLA-A24 allele is found in 60% of Japanese, 20% of
Caucasians and 12% of Africans (Imanishi et al, 1992). We have
recently identified tumour-epitopes of the SART3 antigen on
HLA-A0207 molecules, which are able to induce HLA-A2-
restricted and tumour-specific CTLs in the PBMCs of epithelial
cancer patients (Ito et al, unpublished results). The HLA-A2 allele
is found in 40% of Japanese, 50% of Caucasians and 12% of
Africans (Imanishi et al, 1992). 
918 Y Suefuji et al 
British Journal of Cancer (2001) 84(7), 915–919 © 2001 Cancer Research Campaign
0 2 04 06 0
HIVenv
SART3 315-323
SART3 109-118
No peptide
P
a
t
i
e
n
t
 
2
0 2 04 06 0 1 0 0 80
HIVenv
SART3 315-323
SART3 109-118
No peptide
P
a
t
i
e
n
t
 
2
0 1 02 03 04 0
HIVenv
SART3 315-323
SART3 109-118
No peptide
P
a
t
i
e
n
t
 
1
0 50 100 150
HIVenv
SART3 315-323
SART3 109-118
No peptide
P
a
t
i
e
n
t
 
1
SART3315-323 SART3109-118
SART3315-323 SART3109-118 CD
AB
INF-g production (pg ml-1) INF-g production (pg ml-1)
INF-g production (pg ml-1) INF-g production (pg ml-1)
*
*
*
*
Figure 3 Peptide specificity of CTL sublines was established by incubation of the PBMCs of patients 1 and 2, which had been stimulated with the SART3109–118
or SART3315–323 peptide. HLA-A2402-binding HIV peptide (RYLRDQQLLGI) was used as a negative control. One of six or three of 20 sublines from the PBMCs
of patient 1, when stimulated with the SART3109–118 peptide or SART3315–323 peptide, produced a significant amount of IFN-g by recognition of C1R-A2402 cells
pulsed with a corresponding peptide, respectively (A, B). Similarly, one of three or four of 20 sublines from the PBMCs of patient 2, when stimulated with the
SART3109–118 peptide or SART3315–323 peptide, produced a significant amount of IFN-g by recognition of C1R-A2402 cells pulsed with a corresponding peptide,
respectively (C, D). The other sublines failed to show peptide specificity. Values represent the mean of duplicate assays. The two-tailed Student’s t-test was
employed for statistical analysis (*P ≤ 0.05) Subsequently, the SART3 antigen and its peptides could be an
appropriate molecule for use in specific immunotherapy of HLA-
A24+ or -A2+ breast cancer patients. These findings could provide
important information for the development of a specific immuno-
therapy for a relatively large number of breast cancer patients all
over the world.
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